文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

评估立体定向体部放疗相对于雄激素受体信号抑制剂在寡转移性前列腺癌中的作用

Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2021-09-28

单机构回顾性分析35例雄激素受体信号抑制剂(ARSI)耐药寡转移去势抵抗性前列腺癌(omCRPC)患者,SBRT治疗后63%患者PSA下降超过50%,中位无进展生存期(PFS)9.0个月。不完全消融与更差PFS相关(HR 4.21),完全消融亚组中位PFS 13.1个月。作者认为SBRT可能增强ARSI疗效,需前瞻性研究。

要点

  • 35例ARSI耐药omCRPC患者SBRT后63%达成PSA下降>50%,中位PFS 9.0个月。
  • 不完全消融与更差PFS相关(HR 4.21,95%CI 1.74-10.19;P<.01)。
  • 22例完全消融患者中位PFS 13.1个月,1年总生存率93.1%。

核心结论

  • SBRT可能增强ARSI在omCRPC中的疗效,前提是所有病灶接受消融剂量放疗。
  • 未来需对接受ARSI的男性开展SBRT的前瞻性研究。

研究设计与样本

  • 单机构回顾性分析,纳入雄激素受体信号抑制剂(ARSI)耐药、寡转移、去势抵抗性前列腺癌(omCRPC)男性患者。
  • 干预为立体定向体部放疗(SBRT),共35例患者、65个病灶接受治疗。
  • 结局指标为PSA下降大于50%和中位无进展生存期(PFS,PSA或影像学进展),采用Cox回归分析影响PFS的因素。

主要发现

  • 35例患者中位随访17.2个月,63%的患者达成PSA下降大于50%。
  • 中位PFS为9.0个月。
  • 不完全消融(定义为SBRT后存在未治疗病灶或既往接受过姑息性放疗剂量)与更差PFS相关(风险比4.21 [95%CI 1.74-10.19];P<.01)。
  • 22例接受SBRT完全消融转移灶的亚组患者中位PFS为13.1个月。
  • 1年总生存率为93.1%(95%CI 84.4-100)。

关键数值与推荐

  • PSA下降大于50%的患者比例为63%。
  • 中位PFS为9.0个月。
  • 不完全消融与更差PFS相关,风险比4.21(95%CI 1.74-10.19),P<.01。
  • 完全消融亚组(22例)中位PFS为13.1个月。
  • 1年总生存率93.1%(95%CI 84.4-100)。

临床怎么用

  • 作者认为SBRT可能增强ARSI在omCRPC中的疗效,前提是所有病灶接受消融剂量放疗。
  • 作者提出未来需对接受ARSI的男性开展SBRT的前瞻性研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Outcomes of stereotactic body radiation therapy (SBRT) with respect to androgen receptor signaling inhibitors (ARSI) have not been characterized for oligometastatic prostate cancer. We sought to characterize prostate specific antigen (PSA) response and progression-free survival (PFS) after SBRT among men who have progressed on ARSI therapy in the oligometastatic castration-resistant setting. METHODS AND MATERIALS: A single-institution retrospective analysis was performed for men with ARSI-resistant, oligometastatic, castrate-resistant prostate cancer (omCRPC). Intervention consisted of SBRT. PSA reduction greater than 50% and median PFS (PSA or radiographic progression) as determined by routine care comprised outcome measurements. Cox regression analysis was used to determine factors influencing PFS. RESULTS: Thirty-five men with ARSI-resistant omCRPC and 65 lesions treated with SBRT were followed for a median of 17.2 months. In 63% of men PSA reduction greater than 50% was achieved. Median PFS was 9.0 months. Incomplete ablation (defined as the presence of untreated lesions after SBRT or receipt of prior palliative radiation therapy doses) was associated with worse PFS (hazard ratio 4.21 [1.74-10.19]; P < .01). For a subgroup of 22 men with complete ablation of metastatic sites with SBRT, the median PFS was 13.1 months. One-year overall survival was 93.1% (95% confidence interval, 84.4-100). CONCLUSIONS: SBRT may augment the efficacy of ARSI in omCRPC, provided that all lesions receive ablative radiation doses. Future prospective study of SBRT for men receiving ARSI is warranted.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Brennan V, Spektor A, Sweeney C, et al. Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. Adv Radiat Oncol. 2021. PMID: 35071831. doi:10.1016/j.adro.2021.100808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。